Nicholas McAndrew, MD, MSCE, UCLA Health

Nicholas P. McAndrew, MD, MSCE, discusses the phase 3 HER2CLIMB-02 trial of tucatinib plus trastuzumab emtansine in HER2-positive early breast cancer.

Nicholas P. McAndrew, MD, MSCE, discusses the evolution of the treatment armamentarium for HER2-positive breast cancer, including the HER2CLIMB-02 trial.

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.

A discussion on the use of adjuvant CDK4/6 inhibitors in clinical practice for the treatment of early stage HR+ breast cancer.

Experts in breast cancer share insights on the role of CDK4/6 inhibition in the adjuvant setting for early stage HR+ breast cancer.

Hope S. Rugo, MD, leads the discussion on the new data presented at the 2021 ASCO annual meeting for MammaPrint and Breast Cancer Index for early stage HR+ breast cancer.

The role of genomic assays, including Oncotype DX as reported on in the RxPONDER trial, for the optimal management of early stage HR+ breast cancer is discussed.

Aditya Bardia, MD, MPH, leads the discussion on the use of novel CDK4/6 inhibitors, BCL2 inhibitors, and oral SERDS for the treatment of HR+ metastatic breast cancer.

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, review the optimal management of adverse events associated with alpelisib in HR+ metastatic breast cancer.

Breast cancer experts comment on whether there is a benefit to switching to or continuing on CDK4/6 inhibitors with disease progression for HR+ metastatic breast cancer and discuss the use of tamoxifen for third-line endocrine therapy.

Andrew D. Seidman, MD, presents a case study of a 56-year-old postmenopausal woman diagnosed with stage IIB HR+ breast cancer and leads the discussion on approaching treatment for the given patient.

Dejan Juric, MD, leads the discussion on the role of PIK3CA mutations in HR+ metastatic breast cancer.

Nicholas McAndrew, MD, MSCE, provides final thoughts on findings reported at ASCO 2021 for patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer.

Nicholas McAndrew, MD, MSCE, provides his perspective on real-world clinical outcomes using alpelisib in patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer.

Nicholas McAndrew, MD, MSCE, reviews PIK3CA mutations in HR+/HER2- breast cancer and provides his perspective on the joint analysis of SOLAR-1 and CBYL719X2101 in which patients were given alpelisib and fulvestrant.

Nicholas McAndrew, MD, MSCE, shares his perspectives on the updated overall survival results from the phase 3 MONALEESA-3 trial of postmenopausal patients with HR+/HER2- advanced breast cancer treated with fulvestrant plus or minus ribociclib.

Experts in breast cancer comment on the appropriate patient selection of CDK4/6 inhibitors for the management of HR-positive metastatic breast cancer.

A review of data from key phase 3 clinical trials, including ASCO 2021 updates, assessing the use of CDK4/6 inhibitors with endocrine therapy for the frontline treatment of HR-positive metastatic breast cancer.

Considerations for approaching the treatment of HR-positive metastatic breast cancer through insights on key prognostic factors.

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, discuss when it is appropriate to order molecular testing and the impact of testing on the treatment of HR-positive metastatic breast cancer.